Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm ...

Jefferies said it still regards GSK’s fundamental value as “compelling,” adding that its 2027+ estimates for sales and ...

A Trinity Life Sciences report found that more pharma product launches were successful in 2023 than the year before. Here are ...

Image by Arek Socha from Pixabay November 12, 2024 - By Lorna Fernandes - As fall arrives, so does respiratory syncytial ...

Amid fears of an "extremely high level of violent protests," the Brampton Triveni Mandir and Community Centre has cancelled a Life Certificate Event.